Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam-Reference-Cited by-同舟云学术

Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam

Published:2019-01-01 Issue:1 Volume:26 Page:107327481986377
ISSN:1073-2748
Container-title:Cancer Control
language:en
Short-container-title:Cancer Control

Author:

Hung Kien Do¹,Van Quang Le²,Hoang Gia Nguyen³,Bich Phuong Nguyen Thi¹

Affiliation:

1. Department of Medical Oncology, Vietnam National Cancer Hospital—K Hospital, Hanoi, Vietnam

2. Department of Oncology, Hanoi Medical University, Hanoi, Vietnam

3. Dinh Tien Hoang Institute of Medicine, Hanoi, Vietnam

Abstract

Only limited data are available concerning the long-term outcomes of imatinib treatment among Vietnamese or Asian patients with unresectable or recurrent gastrointestinal stromal tumors (GISTs). Our study, which was conducted in 188 patients, aimed to assess the efficacy of imatinib mesylate against unresectable or recurrent GISTs. Imatinib had a high response rate and long survival. Some predictors favorable for progression-free survival and overall survival are good performance status and response with imatinib. Findings are discussed in relation to clinical practice in low- and middle-income country.

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1073274819863776

Reference19 articles.

1. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

2. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

3. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia

4. Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010

5. Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth;Journal of Cancer Research and Clinical Oncology;2021-01-03

3. BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST;Cell Death & Disease;2019-12

4. Scientific Evidence for Cancer Control in Vietnam;Cancer Control;2019-01-01